Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

During my DPhil, I set out to develop and apply sequencing techniques to Hepatitis B Virus (HBV), a pathogen which causes over a million deaths a year and for which molecular epidemiology is poorly resolved. However, this work was eclipsed by the COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which rapidly became the world’s biggest viral killer. I rapidly applied the tools and approaches planned for endemic HBV to tackle pandemic SARS-CoV, implementing whole genome sequencing (WGS) techniques as a translational tool. I established SARS-CoV-2 WGS in my local hospital and explored how sequencing can help track the spread of SARS-CoV-2 in healthcare settings. By combining WGS with epidemiological data, I showed that most hospital-acquired infections result from superspreading events, providing insights to inform infection prevention control (IPC) practice. Returning to work on HBV, I optimised WGS tools, developing methods for HBV WGS, including the easy to use, open-access HEP-TILE protocol. To explore the clinical need for sequencing, I conducted a systematic review and meta-analysis to determine the epidemiology of drug resistance, demonstrating the high genetic barrier for tenofovir resistance compared to entecavir. Using HEP-TILE, I generated HBV genomes from adults with CHB in Uganda, Kenya, South Africa and the Democratic Republic of Congo. I described new HBV strains including recombinants and established the prevalence of resistance associated mutations (RAMs). I also discovered a potential link between a specific HBV polymorphism (S13T) and liver disease (fibrosis/cirrhosis). To further develop insights into HBV treatment, I explored the application of HBV treatment guidelines in Uganda, highlighting the limitations of current non-invasive tests. My thesis demonstrates how viral WGS can be applied to different viruses to enhance public health management. Globally, sequencing expertise and infrastructure gained during the COVID-19 pandemic can be applied to HBV, to support progress towards 2030 elimination targets for viral hepatitis.

Type

Thesis / Dissertation

Publication Date

11/03/2025